Robeco Institutional Asset Management B.V. Has $732.62 Million Stake in Eli Lilly and Company (NYSE:LLY)

Robeco Institutional Asset Management B.V. lifted its holdings in shares of Eli Lilly and Company (NYSE:LLY) by 14.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The institutional investor owned 826,944 shares of the company’s stock after purchasing an additional 104,801 shares during the quarter. Eli Lilly and Company accounts for approximately 1.5% of Robeco Institutional Asset Management B.V.’s portfolio, making the stock its 7th largest position. Robeco Institutional Asset Management B.V. owned about 0.09% of Eli Lilly and Company worth $732,623,000 as of its most recent SEC filing.

Several other institutional investors also recently modified their holdings of the stock. Lansing Street Advisors lifted its position in Eli Lilly and Company by 3.3% in the 3rd quarter. Lansing Street Advisors now owns 648 shares of the company’s stock worth $575,000 after buying an additional 21 shares during the last quarter. BSW Wealth Partners grew its holdings in Eli Lilly and Company by 4.3% in the 3rd quarter. BSW Wealth Partners now owns 3,236 shares of the company’s stock worth $2,867,000 after acquiring an additional 134 shares during the last quarter. Angeles Wealth Management LLC increased its holdings in Eli Lilly and Company by 9.0% during the 3rd quarter. Angeles Wealth Management LLC now owns 4,804 shares of the company’s stock valued at $4,256,000 after purchasing an additional 397 shares during the period. Emerald Advisers LLC increased its stake in shares of Eli Lilly and Company by 75.2% during the third quarter. Emerald Advisers LLC now owns 1,873 shares of the company’s stock valued at $1,659,000 after buying an additional 804 shares during the period. Finally, Van ECK Associates Corp lifted its stake in Eli Lilly and Company by 11.8% in the third quarter. Van ECK Associates Corp now owns 269,469 shares of the company’s stock worth $243,398,000 after acquiring an additional 28,465 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Analyst Ratings Changes

LLY has been the topic of a number of research analyst reports. Berenberg Bank boosted their price objective on shares of Eli Lilly and Company from $1,000.00 to $1,050.00 and gave the company a “buy” rating in a research report on Wednesday, August 14th. Barclays decreased their price target on shares of Eli Lilly and Company from $1,025.00 to $975.00 and set an “overweight” rating for the company in a research note on Thursday. Cantor Fitzgerald reaffirmed an “overweight” rating and set a $885.00 price objective on shares of Eli Lilly and Company in a research report on Monday, September 16th. Evercore ISI upgraded Eli Lilly and Company to a “hold” rating in a report on Thursday, September 5th. Finally, Sanford C. Bernstein assumed coverage on Eli Lilly and Company in a research note on Thursday, October 17th. They issued an “outperform” rating and a $1,100.00 target price for the company. Three equities research analysts have rated the stock with a hold rating and sixteen have given a buy rating to the company’s stock. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $1,009.00.

Eli Lilly and Company Stock Performance

Shares of LLY stock opened at $818.93 on Monday. The company has a market capitalization of $777.43 billion, a price-to-earnings ratio of 88.53, a price-to-earnings-growth ratio of 3.13 and a beta of 0.43. The company has a debt-to-equity ratio of 2.03, a quick ratio of 0.87 and a current ratio of 1.27. Eli Lilly and Company has a one year low of $561.65 and a one year high of $972.53. The company’s 50-day moving average is $911.04 and its 200 day moving average is $866.97.

Eli Lilly and Company (NYSE:LLY) last posted its earnings results on Wednesday, October 30th. The company reported $1.18 EPS for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The business had revenue of $11.44 billion during the quarter, compared to the consensus estimate of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The firm’s revenue for the quarter was up 20.4% on a year-over-year basis. During the same period in the previous year, the business posted $0.10 EPS. Sell-side analysts expect that Eli Lilly and Company will post 13.23 EPS for the current fiscal year.

Eli Lilly and Company Announces Dividend

The business also recently disclosed a quarterly dividend, which will be paid on Tuesday, December 10th. Investors of record on Friday, November 15th will be given a dividend of $1.30 per share. The ex-dividend date is Friday, November 15th. This represents a $5.20 dividend on an annualized basis and a yield of 0.63%. Eli Lilly and Company’s dividend payout ratio (DPR) is 56.22%.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.